Document ID: chunk:federal_register_of_legislation:F2021L00618:reg:9:p2
Version: federal_register_of_legislation:F2021L00618
Segment Type: reg
Provision Reference: reg 9 (pt 2/2)
Character Range: 6322–7809

IgA nephropathy during drug therapy and either:
(a)          the improvement of IgA nephropathy within 3 months of discontinuing or tapering drug therapy; or
(b)          the clinical worsening of IgA nephropathy on rechallenge with the same drug; and
where taking the drug continued for at least the 7 days before the clinical worsening of IgA nephropathy;
(13)      taking a biologic agent for the treatment of cancer or autoimmune disease for at least the 7 days before the clinical worsening of IgA nephropathy;
Note: biologic agent is defined in the Schedule 1 - Dictionary.
(14)      undergoing kidney transplantation before the clinical worsening of IgA nephropathy;
(15)      being overweight or obese for at least the 5 years before the clinical worsening of IgA nephropathy;
Note: being overweight or obese is defined in the Schedule 1 - Dictionary.
(16)      having smoked at least 5 pack-years of tobacco products in the 10 years before the clinical worsening of IgA nephropathy;
Note: one pack-year is defined in the Schedule 1 - Dictionary.
(17)      inhaling, ingesting or having cutaneous contact with an organic solvent in an unventilated and confined space:
(a)          for an average of at least 2 hours per week; and
(b)          for at least 1 year within the 5 years before the clinical worsening of IgA nephropathy;
Note: organic solvent is defined in the Schedule 1 - Dictionary.
(18)      inability to obtain appropriate clinical management for IgA nephropathy.